Silence Therapeutics Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Silence Therapeutics Plc (SLN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Silence Therapeutics Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 111,006M combined for its competitors (0.0% combined share).
- Scale: Silence Therapeutics Plc ranks #84 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer differentiation: Revenue per employee of $0.01M compares with $1.07M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Silence Therapeutics Plc vs. its Competitors, Q2 2026
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Silence Therapeutics Plc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Silence Therapeutics Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Silence Therapeutics Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Silence Therapeutics Plc's competitor groups requires a Commercial License.
Silence Therapeutics Plc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Silence Therapeutics Plc | - | - | - | Yes |
| Competitors combined (44) | ||||
| High-Confidence Competitors (1) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SLN Stock Performance relative to its Competitors
SLN Stock Performance relative to High-Confidence Competitors
SLN Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | An2 Therapeutics Inc | 282.9% | Outperformed |
| 3 | Regulus Therapeutics Inc | 282.9% | Outperformed |
| 4 | Apellis Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Kalvista Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Silence Therapeutics Plc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Silence Therapeutics Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Silence Therapeutics Plc |
2,798.70 | 0.84 |
 Pfizer Inc |
168,101.73 | 63,625.00 |
 Vertex Pharmaceuticals Inc |
140,582.02 | 12,951.60 |
 Moderna Inc |
107,062.00 | 2,228.00 |
 Regeneron Pharmaceuticals Inc |
97,147.78 | 16,896.20 |
 United Therapeutics Corporation |
26,676.67 | 3,154.50 |
| SUBTOTAL | 645,009.10 | 120,944.98 |
Sign in to see all competitors of Silence Therapeutics Plc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Silence Therapeutics Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Silence Therapeutics Plc's Competitors Named by the Company
Competitive relationships identified from Silence Therapeutics Plc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Protagonist Therapeutics inc | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Arrowhead Pharmaceuticals Inc | Company report | 85% |
| Wave Life Sciences Ltd | Company report | 85% |
| Ionis Pharmaceuticals Inc | Company report | 85% |
| Dicerna Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Silence Therapeutics Plc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Silence Therapeutics Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Ptc Therapeutics inc | Life Science Segment 100.00 % |
| Apellis Pharmaceuticals Inc | Reportable Segment Aggregation Before Other Operating Segment 100.00 % |
| Ionis Pharmaceuticals Inc | Ionis Operations 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Silence Therapeutics Plc.
Silence Therapeutics Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Silence Therapeutics Plc | 2,799 | 9,534 | -681,284 |
| Pfizer Inc | 168,102 | 848,333 | 54,160 |
| Vertex Pharmaceuticals Inc | 140,582 | 31,979,259 | 9,817,037 |
| Moderna Inc | 107,062 | 474,043 | -670,426 |
| Regeneron Pharmaceuticals Inc | 97,148 | 1,096,444 | 312,615 |
| United Therapeutics Corporation | 26,677 | 2,253,214 | 936,357 |
| PEERS TOTAL | 642,210 | 1,073,570 | 77,794 |
Sign in to see all peers for Silence Therapeutics Plc.
Silence Therapeutics Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Pfizer Inc | United States 63.93 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| United Therapeutics Corporation | UNITED STATES 97.12 % |
| Ptc Therapeutics inc | All Other Countries Other Than Russia Brazil and United States 18.85 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Silence Therapeutics Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Silence Therapeutics Plc's industry classification, broader than the peer set above. Market cap in millions of $.Silence Therapeutics Plc ranks #84 of 495 companies by market capitalization in its industry, holding 0.05 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 885, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,232,412 | 20.92 % |
| 2 | Johnson and Johnson | 679,690 | 11.54 % |
| 3 | Beone Medicines Ltd | 623,340 | 10.58 % |
| 4 | Abbvie Inc | 514,617 | 8.74 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 84 | Silence Therapeutics Plc | 2,797 | 0.05 % |
Market cap and industry share for the rest of Silence Therapeutics Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Silence Therapeutics Plc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 79 | Viking Therapeutics Inc | 3,123 | -27.93 % |
| 80 | Bausch Health Companies Inc | 3,106 | 22.80 % |
| 81 | Disc Medicine Inc | 3,023 | -10.18 % |
| 82 | Dyne Therapeutics Inc | 2,990 | -0.74 % |
| 83 | Ideaya Biosciences Inc | 1,234 | 12.3% |
| 84 | Silence Therapeutics Plc | 2,797 | 205.97 % |
| 85 | Xencor Inc | 1,234 | 12.3% |
| 86 | Xeris Biopharma Holdings Inc | 1,234 | 12.3% |
| 87 | Mbx Biosciences Inc | 1,234 | 12.3% |
| 88 | Palvella Therapeutics Inc | 1,234 | 12.3% |
| 89 | Schrodinger Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Silence Therapeutics Plc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Silence Therapeutics Plc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (445 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.5x | - |
| P/B | 17.8x | 4.3x | +13.5x |
| Return on Equity | -106.94 % | industry aggregate | -123.29 % |
| Return on Invested Capital | -41.16 % | -9.84 % (avg) | -31.32 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Silence Therapeutics Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | - | 43.17 % | - | -98.71 % |
| Operating Margin | -369.02 % | - | - | - |
| Return on Invested Capital | -36.72 % | -135.64 % | -128.64 % | -39.68 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Silence Therapeutics Plc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Silence Therapeutics Plc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Silence Therapeutics Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 885 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Silence Therapeutics Plc's dedicated Suppliers and Customers pages, not here.
Silence Therapeutics Plc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Silence Therapeutics Plc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Silence Therapeutics Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 123.3 points below the industry aggregate.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (46.50 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-4.5% annualized).
Methodology: see Methodology: SWOT Analysis.
Silence Therapeutics Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Silence Therapeutics Plc | 3.16 | 8.30 | - |
| Pfizer Inc | 0.04 | 1.27 | 0.72 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| United Therapeutics Corporation | 2.58 | 5.86 | - |
Sign in to see all peers for Silence Therapeutics Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Silence Therapeutics Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Silence Therapeutics Plc | Q2 2026 | - | - |
| Pfizer Inc | Q3 2026 | -0.4 % | -8.7 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| United Therapeutics Corporation | Q2 2026 | -1.9 % | +7.6 % |
| PEERS TOTAL | +8.6 % | +47.4 % |
Sign in to see all peers for Silence Therapeutics Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Silence Therapeutics Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Silence Therapeutics Plc | Q2 2026 | - | - |
| Pfizer Inc | Q3 2026 | -3.5 % | -4.8 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| United Therapeutics Corporation | Q2 2026 | +13.6 % | +73.6 % |
Sign in to see all peers for Silence Therapeutics Plc.
Silence Therapeutics Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Silence Therapeutics Plc | - | - | - |
| Pfizer Inc | 1.98% | 2.34% | 4.62% |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Moderna Inc | - | - | - |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
| United Therapeutics Corporation | 17.98% | 19.53% | 20.18% |
Sign in to see all peers for Silence Therapeutics Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Silence Therapeutics Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Silence Therapeutics Plc | - | 3,335.75 |
| Pfizer Inc | 41.60 | 2.64 |
| Vertex Pharmaceuticals Inc | 35.52 | 10.85 |
| Moderna Inc | - | 48.05 |
| Regeneron Pharmaceuticals Inc | 20.35 | 5.75 |
| United Therapeutics Corporation | 20.91 | 8.46 |
| PEERS AVERAGE | 74.11 | 5.33 |
Sign in to see all peers for Silence Therapeutics Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.